ADC Therapeutics (ADCT) Cash from Operations (2023 - 2026)

ADC Therapeutics has disclosed Cash from Operations across 4 years of filings, most recently posting 29710000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 29710000.0, up 47.26% year-over-year; the trailing twelve-month figure through Mar 2026 was 114550000.0 (up 15.82% YoY), and the FY2025 annual result was 141174000.0, down 14.0% from the prior year.
• Cash from Operations came in at 29710000.0 for Q1 2026 at ADC Therapeutics, up from 31123000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 15392000.0 in Q1 2023 to a low of 56334000.0 in Q1 2025.
• The 4-year median for Cash from Operations is 31123000.0 (2025), against an average of 31800384.62.
• Across the five-year window, Cash from Operations plunged 186.48% in 2024 and jumped 47.26% in 2026, its largest moves.
• ADC Therapeutics' Cash from Operations stood at 31633000.0 in 2023, then jumped by 30.92% to 21852000.0 in 2024, then sank by 42.43% to 31123000.0 in 2025, then increased by 4.54% to 29710000.0 in 2026.
• The last three Cash from Operations figures came in at 29710000.0 (Q1 2026), 31123000.0 (Q4 2025), and 29630000.0 (Q3 2025), per Business Quant data.